Silencing SIX1 inhibits epithelial mesenchymal transition through regulating TGF-β/Smad2/3 signaling pathway in papillary thyroid carcinoma

被引:14
|
作者
Min, Wen-Pu [1 ]
Wei, Xiao-Feng [1 ]
机构
[1] Yangtze Univ, Peoples Hosp Jingzhou City 1, Dept Nucl Med, Affiliated Hosp 1, Jingzhou 434000, Hubei, Peoples R China
关键词
Papillary thyroid carcinoma; SIX1; TGF-beta/Smad2/3; Epithelial mesenchymal transition; POOR-PROGNOSIS; CANCER; EXPRESSION; GROWTH; EMT; METASTASIS; CELLS; OVEREXPRESSION; ACTIVATION; TGF-BETA-1;
D O I
10.1016/j.anl.2020.10.002
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Objective: To investigate the sineoculis homeobox homolog 1 (SIX1) affect the epithelial mesenchymal transition (EMT) in papillary thyroid carcinoma (PTC) through regulating TGF-beta/Smad2/3 signaling pathway. Methods: The SIX1 expression in cytological specimens, tissues or PTC cell lines was detected by qRT-PCR, western blotting or immunohistochemistry. A series of vitro experiments including flow cytometry, CCK-8, wound-healing and Transwell were used to evaluate the biological characteristics in a PTC cell line (NPA cells), which were divided into Blank, Negative control (NC), SIX1, SIX1-siRNA, LY-364947 (TGF-beta/Smad2/3 pathway inhibitor) and SIX1 + LY364947 groups. TGF-beta/Smad2/3 pathway and EMT related protein expression were measured by qRT-PCR and western blotting. Results: SIX1 mRNA expression was increased in cytological specimens from PTC patients as compared with the non-toxic nodular goitre (NTG) patients. Moreover, compared with adjacent normal tissues, expressions of SIX1, N-cadherin and Vimentin were higher while E-cadherin was lower in PTC tissues; and SIX1 was positively correlated with N-cadherin and Vimentin but was negatively correlated with E-cadherin. Furthermore, the SIX1 expression was associated with histopathology, extrathyroidal extension (ETE), lymph node metastasis (LNM), pT stage, TNM stage, and distant metastasis. In addition, the expressions of TGF-beta 1, p-SMAD2/3, N-cadherin and Vimentin were downregulated in NPA cells after LY-364947 treatment with upregulated Ecadherin, decreased cell proliferation and metastasis, and enhanced cell apoptosis, which was reversed by SIX1 overexpression. Conclusion: Silencing SIX1 can inhibit TGF-beta/Smad2/3 pathway, thereby suppressing EMT in PTC, which may be a novel avenue for the treatment of PTC. (C) 2020 Oto-Rhino-Laryngological Society of Japan Inc. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:487 / 495
页数:9
相关论文
共 50 条
  • [41] Dulaglutide Ameliorates Intrauterine Adhesion by Suppressing Inflammation and Epithelial-Mesenchymal Transition via Inhibiting the TGF-β/Smad2 Signaling Pathway
    Wang, Yifan
    Wang, Yixiang
    Wu, Yang
    Wang, Yiqing
    PHARMACEUTICALS, 2023, 16 (07)
  • [42] NR4A1 inhibits the epithelial-mesenchymal transition of hepatic stellate cells: Involvement of TGF-β-Smad2/3/4-ZEB signaling
    Huang, Qian
    Xu, Jingying
    Ge, Yanyan
    Shi, Yue
    Wang, Fei
    Zhu, Mingli
    OPEN LIFE SCIENCES, 2022, 17 (01): : 447 - 454
  • [43] MnTE-2-PyP Attenuates TGF-β-Induced Epithelial-Mesenchymal Transition of Colorectal Cancer Cells by Inhibiting the Smad2/3 Signaling Pathway
    Yang, Yu
    Zhang, Pei
    Yan, Ruicheng
    Wang, Qi
    Fang, Erhu
    Wu, Hongxue
    Li, Shijun
    Tan, Haiyan
    Zhou, Xing
    Ma, Xianxiong
    Tang, Yu
    Huang, Yongming
    Deng, Rui
    Liu, Ying
    Tong, Shilun
    Wang, Zhihua
    Oberley-Deegan, Rebecca E.
    Tong, Qiang
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2019, 2019
  • [44] Stachydrine inhibits TGF-β1-induced epithelial-mesenchymal transition in hepatocellular carcinoma cells through the TGF-β/Smad and PI3K/Akt/mTOR signaling pathways
    Chen, Xiangni
    Yan, Ning
    ANTI-CANCER DRUGS, 2021, 32 (08) : 786 - 792
  • [45] Salvanic acid B inhibits myocardial fibrosis through regulating TGF-β1/Smad signaling pathway
    Gao, Hongyan
    Bo, Zhe
    Wang, Qin
    Luo, Ling
    Zhu, Haiyi
    Ren, Yi
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 110 : 685 - 691
  • [46] RUNX3 inhibits the invasion and migration of esophageal squamous cell carcinoma by reversing the epithelial-mesenchymal transition through TGF-β/Smad signaling
    Xiao, Zhaohua
    Tian, Yu
    Jia, Yang
    Shen, Qi
    Jiang, Wenpeng
    Chen, Gang
    Shang, Bin
    Shi, Mo
    Wang, Zhou
    Zhao, Xiaogang
    ONCOLOGY REPORTS, 2020, 43 (04) : 1289 - 1299
  • [47] Isoliquiritigenin Reverses Epithelial-Mesenchymal Transition Through Modulation of the TGF-β/Smad Signaling Pathway in Endometrial Cancer
    Chen, Hsin-Yuan
    Chiang, Yi-Fen
    Huang, Jia-Syuan
    Huang, Tsui-Chin
    Shih, Yin-Hwa
    Wang, Kai-Lee
    Ali, Mohamed
    Hong, Yong-Han
    Shieh, Tzong-Ming
    Hsia, Shih-Min
    CANCERS, 2021, 13 (06) : 1 - 20
  • [48] Nintedanib inhibits epithelial-mesenchymal transition in A549 alveolar epithelial cells through regulation of the TGF-β/Smad pathway
    Ihara, Hiroaki
    Mitsuishi, Yoichiro
    Kato, Motoyasu
    Takahashi, Fumiyuki
    Tajima, Ken
    Hayashi, Takuo
    Hidayat, Moulid
    Winardi, Wira
    Wirawan, Aditya
    Hayakawa, Daisuke
    Kanamori, Koichiro
    Matsumoto, Naohisa
    Yae, Toshifumi
    Sato, Tadashi
    Sasaki, Shinichi
    Takamochi, Kazuya
    Suehara, Yoshiyuki
    Ogura, Dai
    Niwa, Shin-ichiro
    Suzuki, Kenji
    Takahashi, Kazuhisa
    RESPIRATORY INVESTIGATION, 2020, 58 (04) : 275 - 284
  • [49] Isoliensinine Attenuates Renal Fibrosis and Inhibits TGF-β1/Smad2/3 Signaling Pathway in Spontaneously Hypertensive Rats
    Yao, Mengying
    Lian, Dawei
    Wu, Meizhu
    Zhou, Yuting
    Fang, Yi
    Zhang, Siyu
    Zhang, Wenqiang
    Yang, Yanyan
    Li, Renfeng
    Chen, Hong
    Chen, Youqin
    Shen, Aling
    Peng, Jun
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2023, 17 : 2749 - 2762
  • [50] MICAL1 Mediates TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Metastasis of Hepatocellular Carcinoma by Activating Smad2/3
    Zhuang, Xun
    Wang, Chunrong
    Ge, Zhenghui
    Wu, Mengjie
    Chen, Mengjiao
    Chen, Zhen
    Hu, Jianghong
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2025,